Browse
Submit Data
Databases
API
Help

Metabolomics,Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Ndufc2 gene contributes to stroke susceptibility in the stroke-prone spontaneously hypertensive rat and it associates with juvenile ischemic stroke occurrence in humans

ABSTRACT: To investigate genetic basis of stroke susceptibility in an animal model of complex human disease, the stroke-prone spontaneously hypertensive rat (SHRSP).

ORGANISM(S): Rattus norvegicus

SUBMITTER: Oliver Hummel

PROVIDER: E-MTAB-3688 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Json Xml

Similar Datasets

Deletion of LOX-1 has protective effects on ischemic brain damage in the genetic background of stroke-prone spontaneously hypertensive rat

Project description:To explore the impact of oxidized low density lipoprotein receptor 1 (Olr1 aka LOX-1) gene on stroke, we newly generate a LOX-1 deficient strain of the genetic background of stroke-prone spontaneously hypertensive rat (SHRSP). We explored circulatory miRNAs as diagnostic biomarkers for cerebral ischemic injury by microarray analysis in related rat strains.

2020-05-19 | E-MTAB-8389 | biostudies-arrayexpress

Deletion of LOX-1 has protective effects on ischemic brain damage in the genetic background of stroke-prone spontaneously hypertensive rat

2020-05-19 | E-MTAB-8388 | biostudies-arrayexpress

Transcription profiling of stroke-prone spontaneously hypertensive (SHRSP) rats treated with either an angiotensin II receptor (AT1R) antagonist or an angiotensin converting enzyme (ACE) inhibitor

Project description:Renin-angiotensin system (RAS) inhibition reduces stroke and improves brain capillary integrity in stroke prone spontaneously hypertensive rats (SHRSP). We tested the hypothesis that treatment with an angiotensin II receptor subtype 1 (AT1R) antagonist has different effects, compared to an angiotensin converting enzyme (ACE) inhibitor, on gene expression in blood-brain barrier (BBB) capillaries. Six weeks old SHRSP were treated with either olmesartan (4 mg/kg, n=20), lisinopril (6 mg/kg , n=20) or remained untreated (n=20). Blood pressure was controlled by tail-cuff measurement. After 5 weeks the animals were sacrificed and cerebral capillaries were isolated. mRNA was extracted and analyzed with rat GeneChip DNA arrays. Additionally, brain histology and monocyte/macrophage infiltrates were determined. Both treatments similarly reduced neurological signs of stroke, stroke mortality, and monocyte/macrophage infiltration, compared to controls. Blood pressure was not influenced significantly by both drugs. We found 42 transcripts that were regulated by both treatments in the same manner. These genes were mostly related to inflammation. We also observed 39 differentially expressed genes between the two treatment groups that typically contribute to cell growth and differentiation. This study demonstrates that, despite similar effects on cerebral pathology and outcome, ACE inhibition and AT1R blockade have distinct molecular effects on gene expression in BBB capillaries.

2007-10-31 | E-GEOD-1548 | biostudies-arrayexpress

Gene expression in the kidneys of two spontaneously hypertensive rat strains at 3 and 6 weeks of age

Project description:We examined gene expression profiles in the rat kidneys using genome-wide microarray technology, and determined gene expression profiles in 3 rat strains: normotensive WKY, spontaneously hypertensive rats (SHR), and stroke-prone SHR (SHRSP). To identify candidate genes involved in the genesis of hypertension in the SHR strains, we compared the gene expression levels at 3 and 6 weeks of age, isolated 407 genes showing a more than 4-fold increase or a less than 1/4-fold decrease. The rat kidneys derived from normotensive WKY, spontaneously hypertensive rats (SHR), and stroke-prone SHR (SHRSP) were　examined. Each strain was run in triplicate.

2015-07-03 | E-GEOD-41453 | biostudies-arrayexpress

Cpxm2 as a novel candidate for cardiac hypertrophy and failure in hypertension [Illumina]

Project description:To identify novel targets in left ventricular (LV) hypertrophy (LVH) we initiated comparative transcriptome analysis between genetic models derived from stroke-prone spontaneously hypertensive rats (SHRSP) and Fischer (F344). Previous genetic studies in the SHRSP/F344 model confirmed the presence of a major quantitative trait locus (QTL) for LV mass on rat chromosome (RNO) 1. We assigned carboxypeptidase X 2 (Cpxm2) to a genetic locus for LV mass identified in SHRSP. We assigned carboxypeptidase X 2 (Cpxm2) to a genetic locus for left ventricular mass.

2023-07-10 | GSE154326 | GEO

Gene expression in the adrenal glands of two spontaneously hypertensive rat strains at 3 and 6 weeks of age

Project description:We examined gene expression profiles in the rat adrenal glands using genome-wide microarray technology, and determined gene expression profiles in 3 rat strains: normotensive WKY, spontaneously hypertensive rats (SHR), and stroke-prone SHR (SHRSP). To identify candidate genes involved in the genesis of hypertension in the SHR strains, we compared the gene expression levels at 3 and 6 weeks of age, isolated 407 genes showing a more than 4-fold increase or a less than 1/4-fold decrease. The rat adrenal glands derived from normotensive WKY, spontaneously hypertensive rats (SHR), and stroke-prone SHR (SHRSP) wereM-cM-^@M-^@examined. Each strain was run in triplicate.

2013-04-16 | E-GEOD-31457 | biostudies-arrayexpress

Gene expression in the whole brains of two spontaneously hypertensive rat strains at 3 and 6 weeks of age

Project description:We examined gene expression profiles in the rat whole brains using genome-wide microarray technology, and determined gene expression profiles in 3 rat strains: normotensive WKY, spontaneously hypertensive rats (SHR), and stroke-prone SHR (SHRSP). To identify candidate genes involved in the genesis of hypertension in the SHR strains, we compared the gene expression levels at 3 and 6 weeks of age, isolated 407 genes showing a more than 4-fold increase or a less than 1/4-fold decrease. The rat whole brains derived from normotensive WKY, spontaneously hypertensive rats (SHR), and stroke-prone SHR (SHRSP) wereã??examined. Each strain was run in triplicate.

2014-01-24 | E-GEOD-41452 | biostudies-arrayexpress

Gene Expression Following Cardioembolic Stroke

Project description:Blood from subjects with cardioembolic stroke and controls was collected, and the RNA extracted was interrogated and whole genome U133 Affymetrix Arrays. Twenty-three control samples and sixty-nine cardioembolic stroke samples were assayed. Blood from subjects with cardioembolic stroke and controls was collected, and the RNA extracted was interrogated and whole genome U133 Affymetrix Arrays. Twenty-three control samples and sixty-nine cardioembolic stroke samples were assayed. Cardioembolic stroke subjects were analyzed at three time points: less than 3 hours, 5 hours, and 24 hours following the event.

2014-09-02 | E-GEOD-58294 | biostudies-arrayexpress

Effect of Angiotensin II on gene expression in SHRSP cerebral microcapillaries

2004-08-31 | GSE1548 | GEO

Gene expression in brain following stroke

Project description:We have used microarrays to investigate the changes in gene expression at various times after stroke. Our findings reported that gene expression screening can detect known and unknown transcriptional features of stroke. Brain samples were obtained from 9 patients who died from stroke, with the approval of the local Ethics Committee. The patients were aged between 51 and 86 years and had survived between 2-37 days following stroke. Tissue samples were taken from infarct and peri-infarcted zones while controls were obtained from the contralateral hemisphere. We established mRNA expression profiles of the damaged brain tissues between 2 to 6 days, 9 to 20 days, and 26 to 37 days after stroke. RNA from three stroke patients was pooled for each patient survival group.

2010-06-25 | E-GEOD-9391 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data